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Executive Summary 
In 2014, the cost of substance use (SU) in Canada was $38.4 billion— or approximately $1,100 spent for every 
Canadian regardless of age.1 This report presents the estimates of the costs of SU in Canada from 2007 to 
2014 using the most reliable, up-to-date data sources and methods according to the following categories:
• Cost type (healthcare costs, lost productivity costs, criminal justice costs and other direct costs);
• Substance; and
• Province and territory.  
The ability to track costs and trends in harms uniquely caused by specific types of substance will be 
a valuable asset to federal, provincial and territorial efforts aimed at reducing these harms. A better 
understanding of the societal costs associated with different substances can help inform policy decision 
making and resource allocation for law enforcement, and prevention, treatment and harm reduction services. 
Overall Costs of Substance Use
In 2014: 
• Almost 70% of the total costs were due to alcohol and tobacco. 
• The four substances associated with the largest costs were (in order):
• Alcohol, contributing $14.6 billion or 38.1% of the total costs;
• Tobacco, contributing $12.0 billion or 31.2% of the total costs;
• Opioids, contributing $3.5 billion or 9.1% of the total costs; and 
• Cannabis, contributing $2.8 billion or 7.3% of the total costs. 
• The distribution across the cost types was (in order):
• Lost productivity, contributing $15.7 billion or 40.8% of the total costs;
• Healthcare costs, contributing $11.1 billion or 29.0% of the total costs;
• Criminal justice,  contributing $9.0 billion or 23.3% of the total costs; and
• Other direct costs, contributing $2.7 billion or 7.0% of the total costs.
• Per-person costs from SU were highest in the three territories.
1 At the time of this report, the Canadian Institute for Health Information (CIHI) had not been granted permission to provide 
hospitalization data to the research team. Because of this, all per-person estimates do not include costs associated with inpatient 
hospitalization, day surgery and emergency department costs in the province of Quebec. It is expected that this led to an 
underestimation of approximately $750M, or 2% of total cost. All estimates as well as per-person estimates should be considered 
conservative by this margin.   
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Between 2007 and 2014:2,3
• The per-person costs associated with SU increased 5.5% from $1,025 per person in 2007 to 
approximately $1,081 in 2014. 
• The per-person costs associated with alcohol use increased 11.6% from $369 per person in 2007 to 
$412 per person in 2014. 
• Per-person costs increased 19.1% for cannabis ($67 to $79) and 6.8% for tobacco ($315 to $337).
• Per-person costs decreased by 24.6% for cocaine ($84 to $63) and by 17.9% for other substances 
($20 to $16).
Healthcare-related Costs
Healthcare-related costs include inpatient hospitalizations, day surgery treatment episodes, emergency 
department presentations, specialist treatment for SU disorders, the costs of physician time and prescription 
drug costs. 
In 2014: 
• SU-related healthcare costs amounted to $11.1 billion or $345 per person in Canada.4 
• Alcohol and tobacco use contributed over 90% of costs. 
• After alcohol and tobacco, opioids cost the healthcare system the third-highest amount at $313 
million (2.8%). 
• Over 90% of all healthcare-related costs were contributed by inpatient hospital care (26.3%), 
physician time (36.1%) and prescription drug costs (27.7%). 
• Contributing to these costs were the 255,600 hospitalizations attributable to SU, of which 145,800 
(57.0%) were from tobacco and 87,900 (34.4%) from alcohol.
• Per-person healthcare costs from SU were highest in the three territories, reflecting especially high 
rates of alcohol and tobacco use.
Between 2007 and 2014:
• Costs associated with SU-related health care increased 14.8% from $273 per person in 2007 to  
$313 in 2014.5
• Alcohol-related healthcare costs increased 25.9% from $95 to $119 per person.
• Cannabis-related healthcare costs increased 27.9% from $5 to $6 per person.
• Opioid-related healthcare costs increased 22.2% from $7 to $9 per person.
2Throughout this report, costs for all years are presented in 2014 Canadian dollars.
3 All per-person estimates in this report are calculated using the entire population of Canada by year. 
4 Only some healthcare-related data were available for Quebec. This per-person healthcare cost was calculated without Quebec.
5 Only some healthcare-related data were available for Quebec. These national per-person trend estimates include Quebec and therefore 
differ from the $345 indicated above.
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Lost Productivity Costs
Estimates of SU-related lost productivity costs were based on the lost value of work due to premature 
mortality, long-term disability and short-term disability (absenteeism and impaired job performance).
In 2014:
• Lost productivity costs attributable to SU in 2014 were $15.7 billion.
• Lost productivity costs attributable to SU were approximately $441 per person.
• Costs associated with the use of legally available substances, alcohol and tobacco, were estimated to 
contribute just over 75% of all lost productivity costs associated with SU.
• Contributing to these costs were 20,715 SU attributable deaths among those of working age (age < 65) 
and 284,324 productive years of life lost, with alcohol being the leading cause of lost productivity.
Between 2007 and 2014:
• Overall per-person lost productivity costs increased approximately 8.4% from $406 in 2007 to 
$441 in 2014. 
• The largest increase in per-person lost productivity costs were associated with opioids, which 
increased 20.6% from $43 per person in 2007 to $52 per person in 2014. This increase is likely 
due to the increasing number of premature deaths related to opioid use.
Criminal Justice Costs
Criminal justice costs include those associated with police work, courts and corrections. Included in our 
calculations are expenditures for criminal offences that are 100% attributable to SU (i.e., impaired driving and 
drug-related offences that fall under the Controlled Drugs and Substances Act [CDSA]) and criminal offences 
partially attributable to SU (i.e., violent offences such as homicide or assault, and non-violent offences such 
as theft or arson).
In 2014:
• Almost $9 billion was spent on criminal justice associated with SU, which amounts to $252 for every 
Canadian. 
• 43% of partially attributable crimes (i.e., excluding impaired driving and crimes defined under the 
CDSA) would not have occurred if the perpetrator had not been under the influence of or seeking 
alcohol or other drugs. 
• Almost 20% of all violent crime would not have occurred if the perpetrator was not under the 
influence of or seeking alcohol. 
• Alcohol was responsible for the greatest costs to the criminal justice system at $3.2 billion or 35.2% 
of all criminal justice costs.
• Cocaine was responsible for the second-highest SU-related crime costs ($1.9 billion or 20.8%). Only 
11% of this cost was associated with violations of the CDSA (e.g., trafficking, possession), while the 
other 89% were associated with other violent and non-violent crimes. 
• Cannabis was responsible for the third-highest SU-related crime costs ($1.8 billion or 19.7%), of which 
60% of costs were associated with violations of the CDSA. 
Canadian Substance Use Costs and Harms4
Canadian Centre on Substance Use and Addiction 
Between 2007 and 2014: 
• Criminal justice costs decreased 6.1% from approximately $269 per person in 2007 to about $252 per 
person in 2014.
• Despite an overall decrease in crime incidents, charges and incarcerations, criminal justice spending 
associated with alcohol increased 6.0% (from $84 to $89 per person) and cannabis increased by 
27.4% (from $39 to $50 per person).
Other Direct Costs
Other direct costs include estimates for SU-related expenditures across several distinct categories including 
research and prevention, fire damage, motor vehicle damage and workplace costs not already covered in lost 
productivity (e.g., employee assistance programs, drug testing programs and administrative costs associated 
with workers’ compensation).
In 2014: 
• These other direct costs contributed approximately $2.7 billion to the total SU-related cost. This 
amount was the equivalent of $75 per Canadian.
• Alcohol accounted for 50% of other direct costs, followed by cannabis at about 18%.
• Almost $1.7 billion was spent on damage to motor vehicles as a result of SU-related collisions.
• Damage to property due to SU-associated fires amounted to $590 million. 
Implications
The Canadian Substance Use Costs and Harms Working Group suggests that these estimates provide a 
valuable baseline for Canada as major changes and challenges relating to patterns of SU and associated 
harms are under way. At the time of writing, cannabis is soon to be legalized and it will be seen whether rates 
of use and harms increase. Rates of cannabis use and harms are far lower than those for alcohol and tobacco 
and in 2014 were slightly lower than those for opioid drugs. 
The year of focus, 2014, is at the very beginning of the current alarming rise in opioid overdose events in 
Canada. It can be expected that the associated economic costs of opioid use will increase — probably 
quite substantially. Canadian jurisdictions such as British Columbia and Ontario have substantially loosened 
restrictions on the sale of alcohol since 2014, which suggests there could be increasing alcohol-attributable 
harms in future estimates. There could, however, be countervailing trends depending on the extent to which 
increased cannabis use might substitute for the use of alcohol (Baggio, Chong, & Kwon, 2017).
In relation to tobacco use, there is increasing evidence that electronic cigarettes have been taking market 
share and there are grounds for supposing they will be substantially less harmful than smoked tobacco 
(Newton, Dockrell, & Marczylo, 2018). It will be important to monitor the extent to which individuals who 
currently smoke are switching to these products and how new cohorts of young people will elect to smoke 
tobacco versus vaping electronic cigarettes. However, recent Canadian data indicates trends of decreased 
use of tobacco alongside increased use of electronic cigarettes by youth (Hammond, Reid, Cole, & 
Leatherdale, 2017).
It will be important to monitor trends in all these major categories of SU in Canada and their related harms 
and costs over the years ahead. This work provides a foundation that can be built upon as more data sources 
become available. The estimates presented in this report will be updated annually as a support to decision 
makers, policy advisors and researchers.
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6Although this is the case across the entire report, it is especially true when assessing the costs associated with lost productivity 
due to SU-related long-term disability and inpatient hospitalizations. 
Introduction 
This report presents estimates of the overall costs of substance use (SU) in Canada based on the most 
reliable, up-to-date data sources and methods available for the years 2007 to 2014 (the most recent year for 
which comprehensive data were available). In addition, it presents more specific estimates of the economic 
costs associated with a broad range of substances, including alcohol, tobacco, cannabis, opioids, other 
central nervous system (CNS) depressants (e.g., benzodiazepines, barbiturates), cocaine, other CNS 
stimulants (e.g., amphetamine, methamphetamine, ecstasy) and other substances (e.g., hallucinogens, 
inhalants). Estimates are also presented by province/territory and cost type (i.e., healthcare, productivity, 
criminal justice and other direct costs). 
Detailed results and methods are provided in the Canadian Substance Use Costs and Harms: Technical 
Report. The technical report as well as more detailed healthcare results by province/territory, year, substance, 
type of harm, cost type, sex and age group will be available on the project website (www.csuch.ca).
Comparisons with Other Cost Studies
The estimates presented in the report are derived from the costs associated with conditions and events 
fully and partially attributable to SU. The work presented here draws from an international literature that has 
generated economic costs of SU for many countries and includes international guidelines for the conduct of 
such studies (Single et al., 2003). It also owes a great deal to the work conducted in previous Canadian cost 
studies (Rehm et al., 2006; Single, Robson, Xie, & Rehm, 1998). However, because we were able to access 
more comprehensive data sets and take advantage of improved analytic techniques, the estimates in this 
report should not be directly compared to these earlier studies.6
Nonetheless, we understand that people will feel compelled to compare these studies and will note the very 
similar figures arrived at by us (for 2014) and by Rehm and colleagues (for 2002) for the total costs of SU 
in Canada. Between 2007 and 2014, there has been an increase in both the absolute costs of SU and the 
costs of SU per person. We used substantially different and more conservative methods for our estimates of 
healthcare and lost productivity costs than Rehm and colleagues, meaning it is not possible to make a direct 
comparison of these costs. Our methods were, however, more comparable for criminal justice and other 
direct costs. In these areas we estimate a 57% increase in the costs per person between 2002 and 2014. 
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Overall Costs of Substance Use in Canada 
The overall economic cost of SU in Canada in 2014 was estimated to be $38.4 billion.7 This estimate represents a 
cost of approximately $1,100 for every Canadian regardless of age. In 2014, the legally available and most widely 
used psychoactive substances, alcohol and tobacco, contributed almost 70% of these costs. Alcohol accounted 
for about $14.6 billion (38.1%), tobacco accounted for about $12.0 billion (31.2%) and other substances accounted 
for about $11.8 billion (30.7%) of these costs (see Figure 1 and Table 1). Among the currently illegal substances, 
opioids were responsible for slightly higher costs than cannabis in 2014.
Figure 1. Overall costs (in billions) and percentage of total overall costs attributable to substance use by 
substance and cost type, 2014
7 This figure does not include costs associated with inpatient hospitalization, day surgery, and emergency department costs in the 
province of Quebec. A rough calculation based on Ontario per-person costs across these three cost types indicates that this accounts 
for an approximate $760 million or approximately 2%. Therefore, all estimates as well as per-person estimates should be considered 
conservative by this margin.   
Note: These estimates do not include costs associated with inpatient hospitalization, day surgery and emergency department costs in 
the province of Quebec. 
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stimulants
Other 
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Cost estimates included in this report are broken down into four major cost types: 
Healthcare costs associated with inpatient hospitalizations, day surgery treatment episodes, 
emergency department presentations, specialist treatment for SU disorders, the cost of physician’s 
time and drug prescriptions;
Lost productivity costs associated with SU-attributable premature mortality, long-term disability, 
absenteeism and impaired performance on the job (or “presenteeism”);
Criminal justice costs associated with policing, courts and corrections that can be attributed to SU, 
including costs associated with the enforcement of current drug and impaired-driving laws, as well as 
the impact of violent and non-violent crimes that would not have occurred without some SU; and
Other direct costs, a heterogeneous category that includes costs associated with the federal 
funding of research and prevention programs, SU-attributable fire damage, motor vehicle damage, 
drug testing in the workplace, employee-assistance programs and workers’ compensation. 
The costs of SU in Canada in 2014 by cost type are presented in both Figure 2 and Table 1. Productivity 
losses amounted to $15.7 billion or 40.8% of the total costs, while healthcare costs were $11.1 billion (29.0%). 
The third-highest contributor to total SU-related costs was criminal justice with a cost of $9.0 billion or 23.3% 
of the total.
Figure 2. Overall costs (in billions) and percentage of total overall costs attributable to substance use in 
Canada by cost type, 2014
Healthcare
Lost Productivity
Criminal Justice
Other Direct
Total cost: $38.4 billion
Healthcare Lost	production Criminal	justice Other	direct	
$15.7
40.8%
$11.1
29.0%
$9.0
23.3%
$2.7
7.0%
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Table 1. Costs attributable to substance use in Canada (in millions of dollars) in 2014
Substance Alcohol Tobacco Cannabis Opioids
Other CNS 
Depressants
Cocaine
Other CNS 
Stimulants
Other 
Substances
Total
Healthcare costs 4,230.2 5,902.6 208.9 313.1 217.3 77.6 107.4 65.7 11,122.6
Inpatient 
hospitalizations                   
1,092.4 1,630.8 38.8 66.2 49.2 13.3 15.4 17.9 2,923.9
Day surgery 47.5 49.6 0.7 0.3 0.3 0.1 0.0 0.1 98.5
Emergency 
department visits
200.6 114.9 10.7 12.7 11.0 4.1 4.8 1.8 360.6
Specialized SU 
treatment
453.2 n/a 63.0 51.4 7.9 23.3 36.6 3.1 638.4
Physician time 1,413.3 2,280.0 55.6 105.3 86.6 21.6 29.7 24.2 4,016.3
Prescription drugs 1,023.2 1,827.3 40.0 77.2 62.3 15.3 20.9 18.5 3,084.8
Lost productivity 
costs
5,916.4 5,843.9 368.0 1,831.6 684.9 294.1 458.7 261.5 15,659.1
Premature mortality 3,874.1 3,007.4 249.2 1,622.0 521.9 248.0 395.3 210.9 10,128.7
Long-term disability 1,367.4 1,414.4 72.5 117.9 87.2 29.0 41.5 28.1 3,158.0
Short-term disability 
(absenteeism and 
presenteeism)
674.9 1,422.1 46.3 91.7 75.8 17.1 21.9 22.6 2,372.4
Criminal justice 
costs
3,154.2 5.6 a 1,761.3 1,110.4 296.9 1,864.5 575.5 193.2 8,961.6
Policing 1,630.5 n/a 835.2 639.0 163.6 1,055.5 324.2 109.4 4,757.3
Courts 698.3 n/a 342.2 212.5 57.2 359.7 109.6 34.4 1,814.0
Corrections 825.3 n/a 583.8 258.8 76.2 449.3 141.7 49.5 2,384.7
Other direct costs 1,340.3 222.3 480.5 233.6 341.3 6.5 7.4 50.9 2,682.8
Research and 
prevention 
66.4 72.3 a 10.6 14.4 10.6 1.7 1.5 19.8 197.4
Fire damage 430.4 150.0 10.0 n/a n/a n/a n/a n/a 590.4
Motor vehicle 
damage
715.1 n/a 430.5 198.5 311.1 2.5 2.9 28.9 1,689.5
Workplace drug 
testing
7.5 n/a 6.1 7.1 4.6 0.6 0.9 0.6 27.3
Employee-
assistance programs
51.1 n/a 3.3 4.8 0.9 1.7 1.9 0.2 63.9
Workers’ 
compensation 
administrative costs
69.7 n/a 20.0 8.9 14.1 0.1 0.2 1.3 114.3
Total 14,641.1 11,974.3 2,818.7 3,488.6 1,540.4 2,242.7 1,149.0 571.2 38,426.1
Total cost per 
person (in dollars)
412.02 336.97 79.32 98.17 43.35 63.11 32.33 16.07 1,081.35
% of all SU-related 
costs
38.1% 31.2% 7.3% 9.1% 4.0% 5.8% 3.0% 1.5%  100%
Note: a Costs are limited to federal spending on tobacco control and enforcement. Federal spending on tobacco-related prevention efforts are 
captured in the research and prevention costs for tobacco.  
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8 Unless otherwise noted, all cost figures presented in this report have been adjusted for inflation and are presented in 2014 dollars. 
In 2014, the per-person economic costs were estimated to be higher in the territories than the provinces, 
reflecting in particular their higher rates of tobacco smoking and alcohol use and higher cost of health care 
delivery (Figure 3). 
Figure 3. Overall per person costs attributable to substance use by province and territory, 2014
Note: Meaningful per-person costs for Quebec could not be calculated.
Trends in Economic Costs from 2007 to 2014
The cost of SU in Canada has increased approximately 14% from $33.7 billion in 2007 to $38.4 billion in 
2014.8 However, the Canadian population has also increased over that time. The per-person economic costs 
of SU in Canada increased by 5.5% from $1,025 per person in 2007 to $1,081 in 2014.
Over our study period, the per-person costs associated with alcohol use increased 11.6% from $369 per 
person in 2007 to $412 per person in 2014 (Figure 4). Other per-person cost increases were found in relation 
to the use of other CNS depressants (10.0%), tobacco (6.8%) and opioids (0.9%). However, the largest per-
person increase was associated with cannabis costs, which grew by 19.1% from $67 per person in 2007 
to $79 per person in 2014 (Figure 4). However, it is important to note that, compared with alcohol, the per-
person costs for cannabis were still less than one-quarter the per-person costs associated with alcohol 
across all years assessed. Also, as shown in Table 1, the bulk of the costs associated with cannabis use 
are estimated to flow from cannabis-related crime. In 2014, more than 60% of cannabis-related crime costs 
involved violations of the Controlled Drugs and Substances Act. It is expected that crime-related cannabis 
costs will decrease when it is legalized later in 2018. 
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Figure 4. Overall per person costs (2014 CDN) attributable to substance use in Canada by substance, 2007-2014
Note: Due to missing Quebec data, costs are likely 1% to 2% higher than what is reported here. 
Overview of Methods
The economic costs of SU presented in this report have been assessed across four broad areas: healthcare 
costs, lost productivity costs, criminal justice costs and other direct costs. The present study was based on 
the approaches applied in other Canadian and international substance use cost studies (e.g., Collins & Lapsley, 
2008). However, the availability of additional datasets and analytic resources enabled significant methodological 
improvements and refinements in the methods employed across a number of key areas. As a result, the estimates 
presented in this report should not be directly compared with those made in earlier Canadian cost studies.
Wherever possible, current and province/territory-specific data have been used first to estimate relevant harms 
from SU that might generate costs. For example, many hospital admissions caused by SU are clearly identified 
in official diagnostic records (e.g., opioid overdose, SU disorder, alcoholic psychosis). We were able to access 
individual-level data on the economic costs of different types of hospital admissions and then combine these 
data to come up with accurate costs for events that are 100% attributable to SU. However, there are also a large 
number of health conditions and crime events that are only partially attributable to SU. Healthcare and crime 
records cannot always reliably record the contributions of substance use and so an indirect attributable fraction 
approach was used to estimate the proportions of health and crime outcomes that could be considered caused by 
alcohol or other substance use. 
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For example, an association between specific levels of alcohol consumption and colorectal cancer has 
been established (World Health Organization, 2014). However, not all cases of colorectal cancer are caused 
by alcohol use. The attributable fraction approach allows us to estimate the number of cases of colorectal 
cancer in the population that can be considered to be caused by alcohol consumption. To do so we assess 
the risk of developing a condition (in this case, colorectal cancer) that is associated with various quantities 
of alcohol consumption and the proportion of those in a population consuming alcohol at those quantities. 
Using this information we can determine the proportion of all cases of colorectal cancer that is alcohol-
attributable. Multiplying this proportion by the total number of colorectal cancer cases allows us to calculate 
the number of alcohol-attributable cases of colorectal cancer and the costs associated with treating them. 
This procedure is then conducted for all the conditions for which alcohol is causally associated (Centers 
for Disease Control, 2008; World Health Organization, 2014). We then conducted a similar exercise for each 
and every other substance. Thus the healthcare and lost productivity sections of this report were mostly 
completed using a condition-based, epidemiological  attributable fraction approach. In this approach, the 
proportion of each SU-related condition that would be eliminated in the absence of SU was calculated. These 
proportions were used to estimate the healthcare and lost productivity costs incurred within a given year. 
Another critical methodological choice was to use the human capital approach to estimate the impacts 
of premature mortality attributable to SU on lost productivity. However, we did not use this method when 
estimating the impact of long-term disability on lost productivity because we had a direct estimate of the 
extent of long-term disability involving all people of working age (assumed to be 15 to 64 years old) provided 
for most years in a national survey. The methods used were guided by best practices from the field of health 
economics (Koopmanschap & Rutten, 1996; Rehm et al., 2006; Schroeder, 2012; Single et al., 2003).
For the criminal justice section of this report, new attributable fractions were calculated, using rich data 
sources from Correctional Services Canada, to estimate the proportion of crime associated with alcohol 
and the other substance categories. This work represents a major advance in our understanding of the 
association between SU and crime in Canada. 
More details about the attributable fraction approach and how it was applied in estimating the different costs 
are detailed in the technical report. 
Estimation of Substance Use Prevalence
Most of these methodological approaches at some stage required estimates of the prevalence of SU in 
Canada by province/territory, age, sex, year and type of substance. We drew upon multiple national and 
province/territory-specific surveys containing questions on SU (see Table 2). For alcohol and tobacco, survey 
data were complemented with province/territory- and year-specific commercial sales data. For some required 
data elements, there was either insufficient or missing data for direct estimates. Fortunately, there are 
predictable trends by sex, age, year, province/territory and type of substance that were discernible within the 
very large survey datasets available. These consistent trends facilitated accurate modelling to create robust 
estimates of SU exposures where direct survey estimates were unavailable.
Canadian Substance Use Costs and Harms14
Canadian Centre on Substance Use and Addiction 
Table 2. Data sources used to model prevalence estimates
Substance Data Sources
Alcohol CADUMS 2008–2012 (Statistics Canada, 
2017e, 2017f, 2017g, 2017h, 2017i); CTADS 
2013 and 2015 (Statistics Canada, 2017s, 
2017t); CCHS 2005 and 2007–2014 (Statistics 
Canada, 2017j, 2017k, 2017l, 2017m, 2017n, 
2017o, 2017p, 2017q, 2017r); official sales 
from Statistics Canada 2006–2016 (Statistics 
Canada, 2017u)
Tobacco 
CADUMS 2008–2012 (Statistics Canada, 
2017e, 2017f, 2017g, 2017h, 2017i); CTADS 
2013 and 2015 (Statistics Canada, 2017s, 
2017t); CCHS 2005 and 2007–2014 (Statistics 
Canada, 2017j, 2017k, 2017l, 2017m, 2017n, 
2017o, 2017p, 2017q, 2017r); official sales 
from Statistics Canada 2006–2016 (Statistics 
Canada, 2017u)
Cannabis, opioids, other CNS depressants, cocaine, 
other CNS stimulants and other substances 
CADUMS 2008–2012 (Statistics Canada, 
2017e, 2017f, 2017g, 2017h, 2017i); CTADS 
2013 and 2015 (Statistics Canada, 2017s, 
2017t); NWTAS 2012 (Northwest Territories 
Health and Social Services, 2017)
In this project, we used the methods of Rehm and colleagues (2006) as a starting point and then made 
modifications where necessary to estimate new substance categories and in response to the availability 
of different data sources than those used in the 2006 study. In two important respects, we have modified 
methodological approaches to more closely match those found in similar international exercises. First, for 
healthcare and mortality data, we have largely relied on primary diagnoses, the common practice in international 
SU epidemiology (National Center for Chronic Disease Prevention and Health Promotion, 2014; Sherk et al., 2017a). 
Second, Rehm and colleagues estimated the costs of long-term disability for all currently disabled people for the 
year in question (then 2002) and also projected these forward for each individual until the age of 65 years. We 
believe such a forward estimation overestimates the costs of long-term disability, especially in the context of a 
time-series analysis where repeated counting of costs across subsequent years occurs. As such, we restricted 
our estimates to the year of interest, as recommended by Schroeder (2012).
All dollar figures are presented in 2014 Canadian dollars. The national Consumer Price Index was used to 
adjust costs from earlier study years to 2014 dollars (Statistics Canada, 2018d). In addition, results presented 
in this report are presented by calendar year. When available data were organized by fiscal year (FY), they were 
converted into calendar year by allocating 25% of the costs and counts to the following year. For example, when 
converting FY 2011–2012 to calendar years 2011 and 2012, 25% of FY 2010–2011 was added to 2011, 25% of FY 
2011–2012 was added to 2012, and so on. 
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Healthcare-
related Costs 
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Healthcare-related Costs
Cost estimates are provided for SU-attributable inpatient hospitalizations, day surgery treatment episodes, 
emergency department presentations, specialist treatment for SU disorders, the costs of physician time and 
prescription drug costs. Fundamental to these estimates is the use of the attributable fraction approach for 
estimating the proportions of different types of illness or injury that can be attributed to the use of a particular 
substance. The diagnostic information available for hospitalizations is the most reliable and detailed. This 
information was used as a basis for estimating SU-attributable health care in other domains as well. Data 
sources used to develop these estimates are listed in Table 3. For details of methods employed, see the 
Canadian Substance Use Costs and Harms Technical Report.
Table 3. Data sources used to calculate costs of health care related to SU
Substance Data Sources
Substance-use-attributable fractions Alcohol: Calculated using the International Model of 
Alcohol Harms and Policies (Sherk et al., 2017b)
Tobacco: Relative risks taken for 2014 U.S. Surgeon 
General’s Report (National Center for Chronic Disease 
Prevention and Health Promotion, 2014)
Other substances: Relative risks (various) taken 
from the literature on a condition-specific basis (see 
technical report)
Inpatient hospitalizations CIHI: Discharge Abstract Database (DAD) 2006–
2007 to 2014–2015 (Canadian Institute for Health 
Information, 2017a, 2017b, 2017c, 2017d, 2017e, 
2017f, 2017g, 2017h, 2017i)
CIHI: Cost of a Standard Hospital Stay (indicator) 
(Canadian Institute for Health Information, 2017t)
Day surgeries CIHI: DAD 2006–2007 to 2014–2015 (Canadian 
Institute for Health Information, 2017a, 2017b, 2017c, 
2017d, 2017e, 2017f, 2017g, 2017h, 2017i) and 
National Ambulatory Care Reporting System (NACRS) 
2006–2007 to 2014–2015 (Canadian Institute for 
Health Information, 2017j, 2017k, 2017l, 2017m, 
2017n, 2017o, 2017p, 2017q, 2017q, 2017r, 2017s)
CIHI: Cost of a Standard Hospital Stay (indicator) 
(Canadian Institute for Health Information, 2017t)
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Emergency department visits CIHI: NACRS 2006–2007 to 2014–2015 (counts) 
(Canadian Institute for Health Information, 2017j, 
2017k, 2017l, 2017m, 2017n, 2017o, 2017p, 2017q, 
2017q, 2017r, 2017s)
CIHI: Cost of a Standard Hospital Stay (indicator) 
(Canadian Institute for Health Information, 2017t)
Specialized substance use treatment National Treatment Indicator (NTI) Working Group 
data 2009–2010 to 2014–2015 (counts) (Beasley, 
Jesseman, Patton, & National Treatment Indicators 
Working Group, 2012; McQuaid, Di Gioacchino, & 
National Treatment Indicators Working Group, 2017; 
Pirie, Jesseman, Di Gioacchino, & National Treatment 
Indicators Working Group, 2014; Pirie, Jesseman, & 
National Treatment Indicators Working Group, 2013; 
Pirie & National Treatment Indicators Working Group, 
2015; Pirie, Wallingford, Di Gioacchino, McQuaid, & 
National Treatment Indicators Working Group, 2016)
CIHI: DAD 2006–2007 to 2014–2015 (Canadian 
Institute for Health Information, 2017a, 2017b, 2017c, 
2017d, 2017e, 2017f, 2017g, 2017h, 2017i) and 
Cost of a Standard Hospital Stay 2007–2014 (costs) 
(Canadian Institute for Health Information, 2017t)
Literature: Comorbid mental disorders among clients 
in addiction treatment: the costs of care (costs) 
(Urbanoski, Rehm, Lange, & Popova, 2014)
Family physician time CIHI: National Physician Database 2006–2007 to 
2014–2015 (Canadian Institute for Health Information, 
2017s) and Quick Stats Inpatient Hospitalizations 
2007–2014 (Canadian Institute for Health Information, 
2018)
Prescription drugs CIHI: National Health Expenditure Trends 2007–2014 
(Canadian Institute for Health Information, 2017u)
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Results
SU-attributable healthcare costs in 2014 were $11.1 billion. Costs associated with the use of current legally 
available substances, alcohol and tobacco were estimated to contribute approximately 91% of all healthcare 
costs attributable to SU (Figure 5). These costs are broken down by cost type (i.e., inpatient hospitalization 
costs, day surgery costs, emergency department costs, specialized treatment [residential and non-
residential] costs, physician costs and prescription drug costs) by substance (Table 1). 
Figure 5. Healthcare costs (in billions) and percentage of total healthcare costs attributable to substance use 
by substance, 2014
Note: A rough calculation based on Ontario per-person costs and data that were available from Quebec suggests that these per-
person costs are likely conservative by roughly 8%.
Estimated costs by province or territory are largely driven by population size. Direct comparisons can be 
made from the data presented in Figure 6, which presents rates of estimated healthcare costs attributable 
to SU per person. These estimates show that for the whole of Canada (excluding Quebec), healthcare costs 
attributable to SU cost $345 per person on average. Per-person costs were highest in the territories and 
relatively high in Atlantic Canada.
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Figure 6. Healthcare costs per person attributable to substance use in Canada (except Quebec) by province/
territory, 2014
Note: Meaningful per-person costs for Quebec could not be calculated.
As shown in Table 4, contributing to these costs were the estimated 255,600 hospitalizations attributable 
to SU, of which 145,800 were from tobacco and 87,900 from alcohol. By comparison, opioid-attributable 
hospitalizations were estimated to be the third-highest category with almost 7,000 stays.
Table 4. Hospital stays in Canada (not including Quebec) attributable to substance use in 2014 by type of 
substance
Substance Number of Hospitalizations Percentage of Hospitalizations
Alcohol 87,911 34.4%
Tobacco 145,801 57.0%
Cannabis 3,836 1.5%
Opioids 6,982 2.7%
Other CNS depressants 5,534 2.2%
Cocaine 1,572 0.6%
Other CNS stimulants 2,275 0.9%
Other drugs 1,660 0.6%
Total 255,571
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Overall per-person costs associated with SU-related health care increased almost 15% from $273 in 2007 to 
$313 in 2014.9 Alcohol increased 25.9% from $95 to $119 and tobacco increased 9.2% from $152 to $166 over 
this time period (Figure 7). From 2007 to 2014, cannabis increased 27.9% from $5 per person to $6 per person. 
Similar increases were noted for opioids (22.2% increase from $7 to $9) and other CNS stimulants, which 
increased from $2 to $3 (see Figure 7). The exception to this pattern was cocaine, which decreased 60.2% 
from $5 per person in 2007 to $2 per person in 2014.
Figure 7. Per person healthcare costs (2014 CDN) attributable to substance use in Canada by substance, 
2007-2014 
Note: A rough calculation based on Ontario per-person costs and data that were available from Quebec suggests that these per-
person costs are likely conservative by roughly 8%.
Limitations
Prevalence estimates for substances other than alcohol and tobacco for the three territories had to be modelled 
with limited territory-specific survey data on the extent of other types of SU. We were only able to include 
a direct estimate for the prevalence of cannabis use from one survey available for the Northwest Territories 
in 2012 (Northwest Territories Health and Social Services, 2017). Population data from the territories and 
highly consistent patterns in the survey data from the provinces were used to estimate the extent of use of 
prescription and illegal drugs in the territories. It should be noted, however, that more than 90% of the estimated 
harms in the territories are attributable to the use of alcohol and tobacco and that some Canadian Community 
Health Survey data were available to estimate prevalence of use of these two legally available substances.
The absence of direct estimates of SU prevalence in the territories does not affect estimates of conditions that 
are 100% attributable to SU, which account for a large majority of cases (e.g., from SU disorders [the largest 
single category] and overdoses). We also conducted a validation exercise that demonstrated that the ratio of 
100%-attributable conditions to partially attributable conditions in the territories was quite similar to that of the 
provinces. This finding suggests that the modelled estimates for the territories were reasonable.
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9 Only some healthcare-related data were available for Quebec. These national per-person trend estimates include Quebec and 
therefore differ from the $345 indicated above.
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Lost Productivity Costs 
Estimates are provided for the indirect costs associated with SU-related lost productivity (in terms of 
foregone earnings) due to premature mortality, long-term disability, absenteeism and impaired performance 
(“presenteeism”). The human capital approach was the primary method used to estimate lost productivity 
costs due to premature mortality, which assumes the deceased individual cannot be replaced in the 
workforce and their lost income up to the age of retirement is not recoverable. Lost productivity costs 
due to long-term disability, absenteeism and presenteeism were calculated using data from the Canadian 
Community Health Survey. The data sources used to develop these estimates are listed in Table 5. For details 
on the methods employed to produce our estimates, see the Canadian Substance Use Costs and Harms 
Technical Report. 
Table 5. Data sources used to calculate costs of health care related to SU
Substance Data Sources
Premature mortality Vital Statistics – Death Database (Statistics Canada, 
2017v); General Social Survey (Statistics Canada, 
2017d) (counts); Labour Force Survey (Statistics 
Canada, 2017c); Job Vacancy and Wages Survey 
(Statistics Canada, 2017b) (costs)
Long-term disability Canadian Community Health Survey (Statistics 
Canada, 2017j, 2017k, 2017l, 2017m, 2017n, 2017o, 
2017p, 2017q, 2017r) (counts and costs)
Short-term disability (absenteeism  
and presenteeism)
Canadian Community Health Survey (Statistics 
Canada, 2017j, 2017k, 2017l, 2017m, 2017n, 2017o, 
2017p, 2017q, 2017r) (counts and costs)
Results
SU-attributable lost productivity costs in 2014 were $15.7 billion. Costs associated with the use of current 
legally available substances (alcohol and tobacco) were estimated to contribute slightly more than 75% of all 
lost productivity costs associated with SU (see Figure 8). 
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Figure 8. Costs (in billions) of lost productivity attributable to substance use in Canada by substance, 2014
The estimated per-person lost productivity costs attributable to SU for the provinces, territories and Canada 
are presented in Figure 9. For the whole of Canada, lost productivity attributable to SU costs an average of 
$441 per person. Per-person costs were highest in the territories. 
Figure 9. Per person lost productivity costs attributable to substance use in Canada by province/territory, 2014
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Overall per-person lost productivity costs increased by approximately 8.4% from $406 in 2007 to $441 
in 2014. The per-person costs of lost productivity due to alcohol and tobacco both increased by similar 
amounts over the course of the study, with the costs related to alcohol increasing by more than 8% (from 
$153 in 2007 to $166 in 2014) and those related to tobacco increasing by about 6% (from $155 in 2007 to 
$164 in 2014) (Figure 10). The largest increase occurred among opioids, with the per-person cost increasing 
by more than 20% over the course of the study (from $43 per person in 2007 to $52 per person in 2014) 
(Figure 10). This increase is likely due to the growing number of opioid-related premature deaths (Table 6). 
Increased lost productivity costs were also observed among other CNS depressants, with per-person costs 
increasing by 16% from $17 in 2007 to $19 in 2014. The only substance associated with a decrease in lost 
productivity costs was cocaine, with per-person costs falling by more than 22% over the course of the study 
(from $11 per person in 2007 to $8 per person in 2014). 
Underlying these costs are the estimated numbers of deaths and the potential years of productive life lost 
(PYPLL), as shown in Table 6 and Table 7, respectively. Tobacco was the leading cause of the 67,515 SU-
attributable deaths with 47,562 deaths in 2014, followed by alcohol with 14,827 deaths and opioids with 2,396 
deaths. One measure of the toll of SU-attributable mortality is the total number of PYPLLs, which amounted 
to 751,369 in 2014 (Table 6). Tobacco use was the leading cause of PYPPLs with 326,870, followed by alcohol 
with 244,144.
Table 6. Number of deaths, average age at death and potential years of life lost due to substance  
use-attributable premature mortality, 2014
Substance Deaths Average Age 
at Death
Potential Years of Life Lost 
due to Premature Mortality
Alcohol 14,827 65.3 244,144
Tobacco 47,562 75.4 326,870
Cannabis 851 61.8 18,301
Opioids 2,396 45.5 87,782
Other CNS Depressants 796 46.4 28,792
Cocaine 297 38,0 13,015
Other CNS stimulants 487 38.8 21,038
Other drugs 299 44.3 11,427
Total     67,515 71.0 751,369
PYPLLs are calculated up to 65 years of age. Because of the young age at which many alcohol attributable 
deaths and injuries occur, alcohol was leading contributor to the 351,516 SU-attributable PYPLLs with 138,980 
in 2014. Due to the young age of many opioid-related deaths (mean=45.5), opioids contributed as many as 
52,061 PYPLLs.
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Table 7. Number of individuals (age 0–64 years) removed from the workforce and potential years of productive 
life lost due to substance use-attributable premature mortality and long-term disability, 2014
Substance Individuals Removed from 
the Workforce
Potential Years of Productive 
Life Lost
Alcohol      35,777    138,980 
Tobacco 39,727    104,869 
Cannabis 2,109        8,436 
Opioids 4,636      52,061 
Other CNS depressants 2,569      17,443 
Cocaine 883        8,827 
Other CNS stimulants 1,332      13,943 
Other drugs 875        6,957 
Total 87,908 351,516
Figure 10. Per-person lost productivity costs (2014 CDN) attributable to substance use in Canada by substance, 
2007–2014
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Limitations
For our estimates of SU-related long-term disability, we examined the prevalence of individuals who were 
absent from the workforce due to long-term disability and estimates to the year of interest, as recommended 
by Schroeder (2012). This is a different, more conservative method than the one used by Rehm and colleagues 
(2006) as well as in other cost studies. Our results are therefore not directly comparable to the results from 
these earlier studies. For more details about the limitations on the methods used to calculate lost productivity 
costs associated with premature mortality, long-term disability, absenteeism or presenteeism, refer to Chapter 
13 of the Canadian Substance Use Costs and Harms: Technical Report. 
Criminal  
Justice Costs
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Criminal Justice Costs 
Criminal justice costs include those associated with policing, courts and corrections. Included in our 
calculations are expenditures for criminal offences that are 100% attributable and partially attributable to SU. 
The 100% attributable offences include impaired driving as well as drug-related offences that are in violation 
of the Controlled Drugs and Substances Act (CDSA), including the possession, trafficking and production of 
controlled substances. In addition to fully attributable criminal offences, we also included criminal offences 
partially attributable to SU (e.g., violent offences such as homicide or assault, non-violent offences such as 
theft or arson). As described in the Canadian Substance Use Costs and Harms: Technical Report, crime-
attributable fractions for Canadian men and women were estimated based on a comprehensive intake 
survey given to more than 29,000 offenders as they entered federal prisons about the role SU played in their 
offences (see Table 8). Estimates of prevalence of use for each substance were applied to further modify 
these fractions by age, year and region.
The resulting attributable fractions by substance were applied to counts of partially attributable, Criminal 
Code incidents (for policing costs), charges (for court costs) and admissions to correctional facilities (for 
correctional costs). The result was added to the number of fully attributable incidents, charges or admissions, 
and then divided by the total to assess the proportion of SU-attributable counts. The resulting proportions 
were then applied to the total costs associated with policing, court and correction costs by year and 
province/territory. 
Table 8. Data sources used to estimate crime costs attributable to SU
Costs/Harm Data Sources
Crime-related attributable fractions Correctional Service of Canada: Computerized 
Assessment of Substance Abuse (CASA) (Kunic 
& Grant, 2006); Women’s CASA (Correctional 
Service of Canada, 2017)
Police (crime incidents) Uniform Crime Reporting Survey 2009–2014 
(Statistics Canada, 2017a)
Courts (charges) Integrated Criminal Court Survey 2008/09–
2014/15 (Statistics Canada, 2018b)
Corrections (admissions to sentenced custody) Adult Correctional Services 2008/09–2014/15 
(Statistics Canada, 2018a); Youth Custody and 
Community Service Survey 2008/09–2014/15 
(Statistics Canada, 2018c)
Criminal justice costs Office of the Parliamentary Bureau Officer: 
Expenditure Analysis of Criminal Justice in 
Canada, 2013 (Story & Yalkin, 2013); Treasury 
Board of Canada Secretariat: Tobacco Control 
Strategy 2006/07–2014/15 (Treasury Board of 
Canada Secretariat, 2015).
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Results
According to our newly generated attributable fractions, 43% of all partially attributable crimes (i.e., excluding 
impaired driving and crimes defined under the CDSA) are attributable to SU. Alcohol was associated more 
with violent crime (20%) than non-violent crime (8%), while other substances were associated with violent and 
non-violent crime almost equally (26% and 25%, respectively) (see Table 9).
Table 9. Attributable fractions for substance use related crime
Substance Attributable fractions
Violent offences Non-violent offences (excluding 
substance defined offences)
Alcohol 0.199 0.080
Cannabis 0.055 0.027
Opioids 0.047 0.063
Other CNS depressants 0.012 0.010
Cocaine 0.107 0.105
Other CNS stimulants 0.032 0.033
Other substances 0.010 0.010
All substances 0.462 0.328
In 2014, almost $9 billion was spent on SU-attributable criminal justice costs. Alcohol accounted for more 
than one-third of these costs (see Figure 11). Compared to the other cost types examined in this report, 
criminal justice costs associated with tobacco was the lowest of all substances examined. There are few 
tobacco-related offences or correctional costs associated with tobacco and only limited costs related to 
tobacco control and enforcement. 
Following alcohol, cocaine was the substance responsible for the highest costs to the criminal justice system. 
Despite prevalence rates of less than 2% in the Canadian general population, cocaine was associated 
with 10.7% of all violent crime and 10.5% of all non-violent offences (not including 100% SU-attributable 
crimes). Almost 90% of the criminal justice costs associated with cocaine were due to policing, court and 
corrections costs associated with violent and non-violence offences, with the remaining 10% associated with 
violations of the CDSA. In contrast, almost 60% of cannabis-related criminal justice costs were associated 
with violations of the CDSA. Costs incurred from policing crimes related to SU were the highest, followed by 
correctional costs and court costs. 
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Figure 11. Criminal justice costs (in billions) and percentage of total criminal justice costs attributable to substance 
use by substance, 2014
The per-person criminal justice costs of SU in 2014 were $252 (see Figure 12). These costs were highest in Ontario 
and lowest in Manitoba. 
Figure 12. Per person criminal justice costs attributable to substance use in Canada by province/territory, 2014
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Although overall per-person criminal justice costs remained relatively stable between 2007 and 2014, there 
were differences by substance. Per-person criminal justice costs associated with alcohol increased 6% from 
$84 per person in 2007 to $89 per person in 2014 (see Figure 13), and cannabis-related costs increased 27% 
from $39 per person in 2007 to $50 per person in 2014 (see Figure 13). During that same time frame, cocaine- 
and opioid-related per-person costs decreased by 22% and 23%, respectively.
Figure 13. Per person criminal justice costs (2014 CDN) attributable to substance use in Canada by 
substance, 2007–2014
Limitations
Despite having relatively comprehensive data, in some cases imputations were necessary to estimate for 
missing data. For example, linear projections were conducted to estimate policing, courts and corrections 
costs for 2013 and 2014. In addition, costing data were reported only for certain province/territories; therefore, 
imputations were necessary to distribute costs across the provinces/territories for which there were no data. 
Due to changes in the recording of data by certain agencies, we were unable to obtain comparable counts 
for crime incidents and charges prior to 2009. Given that these counts are critical in estimating the criminal 
justice costs attributable to SU, we were unable to provide cost estimates for 2008 and 2009. Instead, we 
used linear trend projection to estimate criminal justice costs attributable to SU for these two years. 
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Other Direct Costs
Other direct costs include estimates for expenditures related to SU across several miscellaneous categories, 
including research and prevention (which are considered policy costs [Single et al., 2003]), fire damage, 
motor vehicle damage and workplace costs not already covered in our review of lost productivity costs (i.e., 
employee assistance programs, drug testing programs and administrative costs associated with workers’ 
compensation).  
The methods used to estimate SU-attributable costs varied significantly across the different categories. 
Some expenditures, such as workplace drug testing and federal spending dedicated to SU research and 
prevention, are considered 100% attributable to SU. For other categories, such as property damage from 
fires or motor vehicle damage attributable to the use of a particular substance, the attributable fraction 
approach was used to estimate the proportion of cost attributable to SU. Methods employed for each 
category are described in detail in the Canadian Substance Use Costs and Harms: Technical Report. The 
data sources used to develop the cost estimates are listed in Table 10. 
Table 9. Data sources used to estimate other direct costs attributable to SU
Costs/Harm Data Sources
Research and prevention Health Canada; Canadian Institute for Health 
Research; Heart and Stroke Foundation; 
Canadian Cancer Society; Canadian 
Partnership Against Cancer; Canadian 
Council for Tobacco Control; Traffic Injury 
Research Foundation; Treasury Board of 
Canada Secretariat: Tobacco Control Strategy 
2006/07–2014/15 
Fire damage Provincial/territorial fire marshal and fire 
commissioners reports 2007–2014; personal 
communications with provincial/territorial fire 
marshals and fire commissioners
Motor vehicle damage National Collision Database (Transport Canada, 
2017) (counts); General Insurance Statistical 
Agency (2017) (costs)
Workplace drug-testing programs Barbara Butler & Associates (2012) (counts and 
costs)
Employee-assistance programs Labour Force Survey 2007–2014 (Statistics 
Canada, 2017c); Macdonald & Wells (1995) 
(counts); personal communications with 
Morneau Shepell (costs)
Workers’ compensation administrative costs Provincial/territorial workers’ compensation 
boards annual reports 2007–2014
Results 
In 2014, close to $2.7 billion was spent on other direct costs attributable to SU. Half of these costs were 
attributable to alcohol (see Figure 14). Cannabis accounted for the second-highest proportion of other direct 
costs at almost 18%. 
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Figure 14. Other direct costs (in billions) and percentage of total other direct costs attributable to substance 
use by substance, 2014
The largest proportion of other direct costs expenditures was associated with motor vehicle damage, which 
accounted for almost $1.7 billion. This was followed by fire damage to property, which totalled $590 million. 
The rates of estimated other direct costs attributable to SU per person are shown in Figure 18. In 2014, for 
Canada as a whole, approximately $75 per person was spent on other direct costs attributable to SU. The 
range in costs was fairly broad across the country with a low of $60 spent per person in Nova Scotia and a 
high of $146 spent per person in the Northwest Territories. 
Figure 15. Per-person other direct costs attributable to substance use in Canada by province/territory, 2014
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The other direct costs associated with the substances assessed in this report were relatively stable from 
2007 to 2011. These yearly cost trends largely mirror those of motor vehicle damage, which is consistent with 
the major contribution of this expenditure category to the total other direct costs. Similar trends are observed 
in the rates of estimated other direct costs attributable to SU per person in Canada for years 2007 to 2014 
(see Figure 16).
Figure 16. Per-person other direct costs (2014 CDN) attributable to substance use in Canada by substance, 
2007–2014
Limitations
Due to the heterogeneous nature of the datasets that were used to estimate other direct costs attributable 
to SU, the unique limitations associated with each dataset are described at the end of each of the cost 
categories in the Canadian Substance Use Costs and Harms: Technical Report. In general, the SU-
attributable other direct costs were largely accounted for by expenditures on motor vehicle damage (63%) 
and fire damage (22%) and so were largely influenced by the limitations associated with these datasets. 
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Strengths and Limitations 
To estimate comprehensively the economic costs of SU across the domains of healthcare, lost productivity, 
crime and miscellaneous direct costs for eight categories of substance, 13 jurisdictions and eight years was, 
needless to say, a substantial undertaking. We have endeavoured to use best practice methodologies and 
the most up-to-date available sources, and to draw on multiple official data sources. Notable strengths of the 
exercise include: 
(i) Use of the latest WHO burden of disease methodologies (Degenhardt et al., 2016) and estimates 
for the contributions of SU to disease and injury as, for example, summarized in the new international 
resource InterMAHP (Sherk et al., 2017b); 
(ii) Use of a comprehensive survey administered to offenders on admission to federal penitentiaries that 
specifically enquires about the role of psychoactive substances in the commission of their crimes; 
(iii) Application of recommended modern methods for estimating impacts on lost productivity from both 
long-term disability and premature mortality (Schroeder, 2012); and 
(iv) Comprehensive modelled estimates of SU prevalence by age, sex, jurisdiction, year and type of 
substance, incorporating data from approximately 150,000 Canadians who have completed various 
national, provincial and territorial surveys. 
Nonetheless, when interpreting the estimates and placing them in context it is important to be aware of some 
limitations and areas of uncertainty. Most of these limitations have been described in the relevant sections of 
the report. However, there are some that apply more broadly and are therefore worth noting. 
First, the burden of disease methodology relies on the assumption that high-quality studies from across the 
world on the association between exposure to substances in a population and disease and injury outcomes 
have universal applicability. While local input data are required on the prevalence of broad categories of 
disease and injury as well as on rates of SU, it is necessary to import assumptions about the risk relationship 
between SU and the incidence of some disease and injury outcomes. We have relied on the latest systematic 
reviews and meta-analyses of the international literature upon which to make best estimates of these risk 
relationships. The evidence base of published studies, however, is stronger in some areas than in others. In 
general, the published literature is stronger in relation to tobacco and alcohol use, and weaker for most illicit 
substances. 
Second, we rely extensively on self-reported data throughout the study. It is well known that self-reported 
levels of SU, particularly for illicit substances, are underestimated to some degree (Zhao, Stockwell, & 
MacDonald, 2009). We are likely therefore to have underestimated the prevalence of SU and associated 
costs. Furthermore, direct estimates from surveys of the prevalence of use different types of substances were 
not available for the years 2007 or 2014, and so estimates generated from a large dataset of available survey 
data and consistent trends available over time and place and by age and sex were incorporated. Direct 
survey data on self-reported SU for the territories were only available for alcohol, tobacco and cannabis 
for some years and extrapolation made for other years based on patterns observed nationally for different 
age and sex groups. Territory-specific estimates of rates of other SU were modelled based on the large set 
of provincial data. Fortunately, the majority (about 70%) of healthcare conditions related to illicit SU can be 
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estimated directly from diagnostic data and do not need to be imputed from self-report survey data using the 
attributable fraction methodology, so this area of uncertainty is relatively small.
Finally, like Rehm and colleagues (2006), we relied heavily on estimates of the contribution of SU to 
hospitalizations given the strong and reliable data available from the Canadian Institute for Health Information. 
The proportional contributions by substance and year to these healthcare events were directly applied to 
other areas of health care including prescription drugs and physician costs. We cannot be certain of course 
of the extent to which these proportional contributions by different types of substance apply to these 
diverse areas of health care. We also inherited limitations in each of the major databases we drew upon for 
our analyses. For example, reports on the extent to which different substances were detected in the blood 
of drivers produced for several years included estimates of these based on the number of single-vehicle 
night-time crashes, which are known to be highly associated with alcohol use. However, the extent of this 
relationship in each jurisdiction and year will vary and these estimates contain a degree of uncertainty.
Despite these limitations and assumptions, we used the most up-to-date, reliable and comprehensive data 
and methods available in developing our estimates. In the future there will no doubt be better data and more 
research available that will allow us to improve on our estimates (as we improved on Rehm et al., 2006). Until 
such data and research become available, we feel confident that we have developed the best estimates 
possible.
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Conclusions and Implications 
The cost estimates given in this report provide a valuable baseline for Canada at a time when major changes 
and challenges are underway in relation to patterns of SU and their related harms. As of the time of writing, 
cannabis will soon be legalized and it will be important to see whether rates of use and harms increase. Rates 
of cannabis use are currently far lower than those for alcohol and tobacco and, in 2014, were slightly lower 
than those for opioid drugs. The year of focus for this report, 2014, is at the very beginning of the current 
alarming rise in opioid overdose events in Canada and it can be expected that the associated economic costs 
of opioid use will increase, probably quite substantially. 
It should also be kept in mind that a number of Canadian jurisdictions, such as British Columbia and 
Ontario, have substantially loosened restrictions on the sale of alcohol since 2014, suggesting there might 
be increasing harms attributable to alcohol in future estimates. However, there could also be countervailing 
trends depending on the extent to which increased cannabis use substitutes for the use of alcohol (Baggio, 
Chong, & Kwon, 2017). 
Regarding tobacco use, there is increasing evidence that electronic cigarettes have been taking market 
share and there are grounds to suggest these will be substantially less harmful. It will be important to monitor 
the extent to which individuals who currently smoke tobacco are switching to these products and also how 
new cohorts of young people choose between smoking tobacco and vaping electronic cigarettes. Recent 
Canadian data indicates decreased use of tobacco alongside increased use of electronic cigarettes by youth 
(Hammond, Reid, Cole, & Leatherdale, 2017). 
It will be necessary to monitor trends in all these major categories of SU in Canada and their related harms 
and costs over the years ahead. The estimates presented in this report will be updated to provide a dynamic, 
continuously updated resource for decision makers, policy advisors and researchers.
Canadian Substance Use Costs and Harms44
Canadian Centre on Substance Use and Addiction 
References
Baggio, M., Chong, A., & Kwon, S. (2017). Helping settle 
the marijuana and alcohol debate: evidence from 
scanner data. Retrieved from https://ssrn.com/
abstract=3063288 
Barbara Butler and Associates. (2012). Recent 
alcohol and drug workplace policies in Canada: 
considerations for the nuclear industry. Ottawa, 
Ont.: Canadian Nuclear Safety Commission.
Beasley, E., Jesseman, R., Patton, D., & National 
Treatment Indicators Working Group. (2012). 
National Treatment Indicators report, 2012. 
Ottawa, Ont.: Canadian Centre on Substance 
Abuse.
Canadian Institute for Health Information. (Accessed 
July 2017a). Discharge Abstract Database (DAD), 
2006/07 [data file]. Ottawa, Ont.: Author. 
Canadian Institute for Health Information. (Accessed 
July 2017b). Discharge Abstract Database (DAD), 
2007/08 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017c). Discharge Abstract Database (DAD), 
2008/09 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017d). Discharge Abstract Database (DAD), 
2009/10 [data file]. Ottawa, Ont.: Author. 
Canadian Institute for Health Information. (Accessed 
July 2017e). Discharge Abstract Database (DAD), 
2010/11 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017f). Discharge Abstract Database (DAD), 
2011/12 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017g). Discharge Abstract Database (DAD), 
2012/13 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017h). Discharge Abstract Database (DAD), 
2013/14 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017i). Discharge Abstract Database (DAD), 
2014/15 [data file]. Ottawa, Ont.: Author.
Canadian Institute for Health Information. (Accessed 
July 2017j). National Ambulatory Care Reporting 
System (NACRS), 2006/07 [data file]. Ottawa, Ont.: 
Author.    
Canadian Institute for Health Information. (Accessed 
July 2017k). National Ambulatory Care Reporting 
System (NACRS), 2007/08 [data file]. Ottawa, Ont.: 
Author.    
Canadian Institute for Health Information. (Accessed 
July 2017l). National Ambulatory Care Reporting 
System (NACRS), 2008/09 [data file]. Ottawa, Ont.: 
Author.    
Canadian Institute for Health Information. (Accessed 
July 2017m). National Ambulatory Care Reporting 
System (NACRS), 2009/10 [data file]. Ottawa, Ont.: 
Author.  
Canadian Institute for Health Information. (Accessed 
July 2017n). National Ambulatory Care Reporting 
System (NACRS), 2010/11 [data file]. Ottawa, Ont.: 
Author.  
Canadian Institute for Health Information. (Accessed 
July 2017o). National Ambulatory Care Reporting 
System (NACRS), 2011/12 [data file]. Ottawa, Ont.: 
Author.  
Canadian Institute for Health Information. (Accessed 
July 2017p). National Ambulatory Care Reporting 
System (NACRS), 2012/13 [data file]. Ottawa, Ont.: 
Author.  
Canadian Institute for Health Information. (Accessed 
July 2017q). National Ambulatory Care Reporting 
System (NACRS), 2013/14 [data file]. Ottawa, Ont.: 
Author.    
Canadian Institute for Health Information. (Accessed 
July 2017r). National Ambulatory Care Reporting 
System (NACRS), 2014/15 [data file]. Ottawa, Ont.: 
Author.    
Canadian Institute for Health Information. (Accessed 
July 2017s). National Physician Database (NPDB), 
2006-2007 to 2014-2015 [data file]. Ottawa, Ont.: 
Author.    
Canadian Institute for Health Information. (Accessed 
December 2017t). Cost of a Standard Hospital Stay 
[data file]. Ottawa, Ont.: Author. 
Canadian Substance Use Costs and Harms
Canadian Centre on Substance Use and Addiction 
45
Canadian Institute for Health Information. (Accessed 
December 2017u). National Health Expenditure 
Trends, 1975 to 2017: Data Tables — Series G [data 
file]. Ottawa, Ont.: Author.    
Canadian Institute for Health Information. (Accessed 
February 2018). Quick Stats Inpatient 
Hospitalizations 2007–2014 [data file]. Ottawa, 
Ont.: Author.    
Centers for Disease Control and Prevention. (2008). 
Alcohol-related disease impact. Atlanta, GA: 
Author.
Collins, D.J., & Lapsley, H.M. (2008). The costs 
of tobacco, alcohol and illicit drug abuse to 
Australian society in 2004/05. Canberra, Australia: 
Department of Health and Ageing. 
Correctional Service of Canada. (Accessed November 
2017). The Women’s Computerized Assessment 
of Substance Abuse (WCASA) [Data file]. Ottawa, 
Ont.: Author.  
Degenhardt, L., Charlson, F., Stanaway, J., Larney, S., 
Alexander, L.T., Hickman, M., . . . Vos, T. (2016). 
Estimating the burden of disease attributable to 
injecting drug use as a risk factor for HIV, hepatitis 
C, and hepatitis B: findings from the Global Burden 
of Disease Study 2013. The Lancet: Infectious 
Diseases, 16(12), 1385–1398.
General Insurance Statistical Agency. (Accessed 
November 2017). Statistical information. Retrieved 
from https://www.gisa.ca/StatisticalInformation
Hammond, D., Reid, J. L., Cole, A. G., & Leatherdale, 
S. T. (2017). Electronic cigarette use and smoking 
initiation among youth: a longitudinal cohort study. 
Canadian Medical Association Journal, 189(43), 
E1328–E1336.
Koopmanschap, M. A., & Rutten, F. F. (1996). A 
practical guide for calculating indirect costs of 
disease. Pharmacoeconomics, 10(5), 460–466.
Kunic, D., & Grant, B. A. (2006). The computerized 
assessment of substance abuse: results from the 
demonstration project (Research report R-173). 
Ottawa, Ont.: Correctional Service of Canada. 
Macdonald, S., & Wells, S. (1995). The prevalence and 
characteristics of employee assistance, health 
promotion and drug testing programs in Ontario. 
Employee Assistance Quarterly, 10(1), 25–60.
McQuaid, R. J., Di Gioacchino, L. A., & National 
Treatment Indicators Working Group. (2017). 
Addiction treatment in Canada: the National 
Treatment Indicators report: 2014–2015 data. 
Ottawa, Ont.: Canadian Centre on Substance Use 
and Addiction.
National Center for Chronic Disease Prevention and 
Health Promotion (US), Office of Smoking and 
Health. (2014). The health consequences of 
smoking—50 years of progress: a report of the 
Surgeon General. Atlanta, GA: Centers for Disease 
Control and Prevention.
Newton, J. N., Dockrell, M., & Marczylo, T. (2018). 
Making sense of the latest evidence on electronic 
cigarettes. The Lancet, 391(10121), 639–642.
Northwest Territories Health and Social Services. 
(Accessed November 2017). Northwest Territories 
Substance Use and Addictions Survey [data file]. 
Yellowknife, NWT: Author.
Pirie, T., Jesseman, R., Di Gioacchino, L., & National 
Treatment Indicators Working Group. (2014). 
National Treatment Indicators report: 2011–2012 
data. Ottawa, Ont.: Canadian Centre on Substance 
Abuse.
Pirie, T., Jesseman, R., & National Treatment Indicators 
Working Group. (2013). National Treatment 
Indicators report: 2010–2011 data. Ottawa, Ont.: 
Canadian Centre on Substance Abuse.
Pirie, T., & National Treatment Indicators Working 
Group. (2015). National Treatment Indicators 
report: 2012–2013 data. Ottawa, Ont.: Canadian 
Centre on Substance Abuse.
Pirie, T., Wallingford, S. C., Di Gioacchino, L. A., 
McQuaid, R. J., & National Treatment Indicators 
Working Group. (2016). National Treatment 
Indicators report: 2013–2014 data. Ottawa, Ont.: 
Canadian Centre on Substance Abuse.
Canadian Substance Use Costs and Harms46
Canadian Centre on Substance Use and Addiction 
Statistics Canada. (Accessed November 2017e) . 
Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) 2008 [data file]. Ottawa, Ont.: Author.    
Statistics Canada. (Accessed November 2017f) . 
Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) 2009 [data file]. Ottawa, Ont.: Author.    
Statistics Canada. (Accessed November 2017g) . 
Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) 2010 [data file]. Ottawa, Ont.: Author.    
Statistics Canada. (Accessed November 2017h) . 
Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) 2011 [data file]. Ottawa, Ont.: Author.    
Statistics Canada. (Accessed November 2017i) . 
Canadian Alcohol and Drug Use Monitoring Survey 
(CADUMS) 2012 [data file]. Ottawa, Ont.: Author.    
Statistics Canada. (Accessed November 2017j). 
Canadian Community Health Survey 2005 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017k). 
Canadian Community Health Survey 2007 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017l). 
Canadian Community Health Survey 2008 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017m). 
Canadian Community Health Survey 2009 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017n). 
Canadian Community Health Survey 2010 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017o). 
Canadian Community Health Survey 2011 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017p). 
Canadian Community Health Survey 2012 [data 
file]. Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017q). 
Canadian Community Health Survey 2013 [data 
file].  Ottawa, Ont.: Author. 
Statistics Canada. (Accessed November 2017r). 
Canadian Community Health Survey 2014 [data 
file]. Ottawa, Ont.: Author. 
Rehm, J., Baliunas, D., Brochu, S., Fischer, B., Gnam, 
W., Patra, J., . . . Taylor, B. (2006). The costs of 
substance abuse in Canada 2002. Ottawa, Ont.: 
Canadian Centre on Substance Abuse. 
Schroeder, S. A. (2012). Incidence, prevalence, and 
hybrid approaches to calculating disability-
adjusted life years. Population Health Metrics, 
10(1), 19.
Sherk, A., Stockwell, T., Rehm, J., Dorocicz, J., & 
Shield, K. D. (2017a). The International Model of 
Alcohol Harms and Policies (version 1.0). Victoria, 
B.C.: Canadian Institute for Substance Use 
Research, University of Victoria. Retrieved from 
https://www.intermahp.cisur.ca
Sherk, A., Stockwell, T., Rehm, J., Dorocicz, J., & 
Shield, K.D. (2017b). The International Model of 
Alcohol Harms and Policies (InterMAHP), version 
1.0: a comprehensive guide to the estimation 
of alcohol-attributable morbidity and mortality. 
Victoria, B.C.: Canadian Institute for Substance 
Use Research, University of Victoria. Retrieved 
from https://www.intermahp.cisur.ca
Single, E., Collins, D., Easton, B., Harwood, H., Lapsley, 
H., Kopp, P., & Wilson, E. (2003). International 
guidelines for estimating the costs of substance 
abuse (2nd ed.). Geneva, Switzerland: World Health 
Organization. 
Single, E., Robson, L., Xie, X., & Rehm, J. (1998). The 
economic costs of alcohol, tobacco and illicit 
drugs in Canada, 1992. Addiction, 93(7), 991–1006.
Statistics Canada. (Accessed June 2017a). Uniform 
Crime Reporting Survey [data file]. Retrieved 
from http://www23.statcan.gc.ca/imdb/p2SV.
pl?Function=getSurvey&SDDS=3302
Statistics Canada. (Accessed August 2017b).  Job 
Vacancy and Wage Survey (JVWS) [data file]. 
Ottawa, Ont.: Author.   
Statistics Canada. (Accessed August 2017c). Table 
282-0087 Labour force characteristics, seasonally 
adjusted, by province (monthly) (Saskatchewan, 
Alberta, British Columbia). Ottawa, Ont.: Author.
Statistics Canada. (Accessed August 2017d). The 
General Social Survey [data file]. Ottawa, Ont.: 
Author.    
Statistics Canada. (Accessed November 2017s). 
Canadian Tobacco, Alcohol and Drugs Survey 
2013 [data file]. Ottawa, ON: Author. 
Statistics Canada. (Accessed November 2017t). 
Canadian Tobacco, Alcohol and Drugs Survey 
2015 [data file]. Ottawa, ON: Author.
Statistics Canada. (Accessed November 2017u).  Table  
183-0023 -  Sales and per capita sales of alcoholic 
beverages by liquor authorities and other retail 
outlets, by value, volume, and absolute volume, 
annual. Retrieved from http://www5.statcan.gc.ca/
cansim/a26?lang=eng&id=1830023
Statistics Canada. (Accessed December 2017v). Vital 
Statistics - Death Database, 2007-2014 [data file]. 
Ottawa, Ont.: Author.   
Statistics Canada. (Accessed January 2018a). Table  
251-0026 -  Adult correctional services, community 
admissions to provincial and territorial programs 
by aboriginal identity, annual (number) [data file]. 
Ottawa, Ont.: Author.
Statistics Canada. (Accessed January 2018b). 
Integrated Criminal Court Survey [data file]. 
Ottawa, Ont.: Author.  
Statistics Canada. (Accessed January, 2018c). 
Youth Custody and Community Service 
Survey 2009–2012 [data file]. Retrieved from 
http://www23.statcan.gc.ca/imdb/p2SV.
pl?Function=getInstanceList&Id=353976
Statistics Canada. (Accessed, February 2018d). Table  
326-0021 — Consumer Price Index (CPI), annual 
(2002=100 unless otherwise noted). Ottawa, Ont.: 
Author.   
Story, R., & Yalkin, T. R. (2013). Expenditure analysis of 
criminal justice in Canada. Ottawa, Ont.: Office of 
the Parliamentary Budget Officer.
Transport Canada. (Accessed December, 2017). 
National Collision Database [Data file]. Retrieved 
from http://wwwapps2.tc.gc.ca/saf-sec-sur/7/
ncdb-bndc/p.aspx?l=en
Treasury Board of Canada Secretariat. (2015). 
Federal Tobacco Control Strategy. Ottawa, Ont.: 
Government of Canada. Retrieved from  
https://www.tbs-sct.gc.ca/hidb-bdih/initiative-eng.
aspx?Hi=34 
Urbanoski, K., Rehm, J., Lange, S., & Popova, S. (2014). 
Comorbid mental disorders among clients in 
addiction treatment: the costs of care. International 
Journal of Alcohol and Drug Research, 3(4),  
297–304.
World Health Organization. (2014). Global status report 
on alcohol and health. Geneva, Switzerland: 
Author.
Zhao, Z., Stockwell, T., & MacDonald, S. (2009). Non-
response bias in alcohol and drug population 
surveys. Drug and Alcohol Review, 28(6), 648–657.

